Eculizumab in kidney diseases
The C5 inhibitor monoclonal antibody, eculizumab, has been approved for the treatment of atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH); however, the efficacy and safety of this drug in treating other complement-related renal diseases has not yet been elucida...
Gardado en:
| Main Authors: | , |
|---|---|
| Formato: | Libro |
| Publicado: |
Society of Diabetic Nephropathy Prevention,
2024-01-01T00:00:00Z.
|
| Subjects: | |
| Acceso en liña: | Connect to this object online. |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|
Internet
Connect to this object online.3rd Floor Main Library
| Número de Clasificación: |
A1234.567 |
|---|---|
| Copia 1 | Dispoñible |